Ribon Therapeutics

OverviewSuggest Edit

Ribon Therapeutics is pioneering the discovery and development of monoPARP (mono ADP-ribose polymerase) inhibitors to block cancer cells’ fundamental ability to survive under stress


TypePrivate
Founded2015
HQCambridge, MA, US
Websiteribontx.com

Latest Updates

Employees (est.) (Jan 2022)52(-1%)
Cybersecurity ratingBMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Ribon Therapeutics

Victoria Richon

Victoria Richon

President and Chief Executive Officer, Director
James Audia

James Audia

Executive Director, Chicago Biomedical Consortium
Ribon Therapeutics

Ribon Therapeutics

Executive Director, Chicago Biomedical Consortium
Jodie Morrison

Jodie Morrison

Chair of The Board Of Directors
Laura Brass

Laura Brass

Managing Director, Novartis Venture Fund
Heike Keilhack

Heike Keilhack

Chief Scientific Officer
Show more

Ribon Therapeutics Office Locations

Ribon Therapeutics has an office in Cambridge
Cambridge, MA, US (HQ)
35 Cambridgepark Dr
Show all (1)

Ribon Therapeutics Financials and Metrics

Summary Metrics

Founding Date

2015

Ribon Therapeutics total Funding

$65 m

Ribon Therapeutics latest funding size

$65 m

Time since last funding

6 months ago

Ribon Therapeutics investors

Ribon Therapeutics's latest funding round in July 2021 was reported to be $65 m. In total, Ribon Therapeutics has raised $65 m
Show all financial metrics

Ribon Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

B

83/100

SecurityScorecard logo

Ribon Therapeutics Online and Social Media Presence

Embed Graph

Ribon Therapeutics Blogs

Ribon Therapeutics Named a “Fierce 15” Biotech Company by Fierce Biotech

Cambridge, MA – September 27, 2021 – Ribon Therapeutics, a clinical stage biotechnology company developing therapeutics targeting stress support pathways, today announced it has been … The post Ribon Therapeutics Named a “Fierce 15” Biotech Company by Fierce Biotech appeared first on Ribon Therapeut…

Ribon Therapeutics Announces Key Management Promotions

Heike Keilhack, Ph.D., Promoted to Chief Scientific Officer Kevin Kuntz, Ph.D., Promoted to Chief Drug Development Officer Cambridge, MA – September 1, 2021 – Ribon … The post Ribon Therapeutics Announces Key Management Promotions appeared first on Ribon Therapeutics.

Ribon Therapeutics Announces Publication in Cancer Cell of Pre-Clinical and Mechanism of Action Data for RBN-2397

Small molecule inhibitor of PARP7 restores Type I interferon signaling in tumor cells Data validate therapeutic strategy of targeting PARP7, a key vulnerability in cancer … The post Ribon Therapeutics Announces Publication in Cancer Cell of Pre-Clinical and Mechanism of Action Data for RBN-2397 appe…

Ribon Therapeutics Secures $65 Million Financing

Proceeds Support Advancement of Lead Product Candidates RBN-2397 and RBN-3143 Through Key Clinical Milestones Cambridge, MA – July 14, 2021 – Ribon Therapeutics, a clinical … The post Ribon Therapeutics Secures $65 Million Financing appeared first on Ribon Therapeutics.

Ribon Therapeutics Appoints Paul Brannelly as Chief Financial Officer

Cambridge, MA – June 28, 2021 – Ribon Therapeutics, a clinical stage biotechnology company developing therapeutics targeting stress support pathways, today announced the appointment of … The post Ribon Therapeutics Appoints Paul Brannelly as Chief Financial Officer appeared first on Ribon Therapeuti…

Ribon Therapeutics Announces Oral Presentation of Positive Interim Data from Phase 1 Trial of RBN-2397 in Patients with Advanced Solid Tumors at 2021 ASCO Annual Meeting

RBN-2397 was well tolerated and demonstrated evidence of target inhibition and preliminary signs of clinical activity One partial response (PR) and nine patients with stable … The post Ribon Therapeutics Announces Oral Presentation of Positive Interim Data from Phase 1 Trial of RBN-2397 in Patients …
Show more

Ribon Therapeutics Frequently Asked Questions

  • When was Ribon Therapeutics founded?

    Ribon Therapeutics was founded in 2015.

  • Who are Ribon Therapeutics key executives?

    Ribon Therapeutics's key executives are Victoria Richon, James Audia and Ribon Therapeutics.

  • How many employees does Ribon Therapeutics have?

    Ribon Therapeutics has 52 employees.

  • Who are Ribon Therapeutics competitors?

    Competitors of Ribon Therapeutics include Venn Therapeutics, Zenith Epigenetics and Entrinsic Bioscience.

  • Where is Ribon Therapeutics headquarters?

    Ribon Therapeutics headquarters is located at 35 Cambridgepark Dr, Cambridge.

  • Where are Ribon Therapeutics offices?

    Ribon Therapeutics has an office in Cambridge.

  • How many offices does Ribon Therapeutics have?

    Ribon Therapeutics has 1 office.